Paper Details

  1. Home
  2. Paper Details

Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.

Author: BardadinKrzysztof, BerakHanna, HorbanAndrzej, Kołakowska-RządzkaAnna, LaskusTomasz, StańczakJanusz J, Walewska-ZieleckaBożena, WasilewskiMarek

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Peginterferon alfa-2a and alfa-2b showed similar efficacy in treating patients infected with HCV genotype 1. SVR was associated with low fibrosis stage and low serum HCV RNA level.
Paper Details　
Original Abstract of the Article :
PURPOSE: This prospective, randomized, single-centre study compared peginterferons alfa-2a and alfa-2b, combined with ribavirin, in treating patients infected with hepatitis C virus (HCV) genotype 1. MATERIAL/METHODS: Hundred-and-one patients received 48 weeks of open-label treatment with peginterf...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.advms.2014.01.005

データ提供：米国国立医学図書館（NLM）

A Battle Against Hepatitis C: Comparing Peginterferons for Genotype 1

The landscape of hepatitis C virus (HCV) infection is a challenging terrain, where researchers are constantly seeking new and effective treatments. This randomized, single-center study delves into the efficacy of two peginterferons, alfa-2a and alfa-2b, in combination with ribavirin for treating patients with HCV genotype 1. The researchers aimed to compare the effectiveness of these two peginterferons in achieving sustained virologic response (SVR), a marker of successful treatment. Their findings suggest that both peginterferons demonstrate comparable efficacy in achieving SVR, providing valuable insights for clinicians in selecting treatment options.

A Close Race: Similar Efficacy for Both Peginterferons

The study found no statistically significant difference in SVR rates between the two peginterferons. While peginterferon alfa-2a showed a trend towards higher rates of early virologic response (EVR), the difference in SVR rates was not substantial. This suggests that both peginterferons are effective in achieving SVR, allowing clinicians to consider individual patient factors and preferences when choosing a treatment approach.

A Strategic Approach: Choosing the Right Weapon for HCV Treatment

This study underscores the importance of individualized care in managing HCV infection. While both peginterferons demonstrate comparable efficacy, the choice of medication may vary depending on individual patient factors, such as fibrosis stage and viral load. It's crucial to consult with healthcare professionals to determine the most appropriate treatment approach for each patient's unique needs.

Dr.Camel's Conclusion

This study is a reminder that the battle against hepatitis C is an ongoing journey. It highlights the importance of careful selection of treatment options based on individual patient factors. Both peginterferons demonstrate promising efficacy, offering clinicians a valuable arsenal of weapons to combat this challenging disease.

Date :
  1. Date Completed 2015-08-19
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

25117425

DOI: Digital Object Identifier

10.1016/j.advms.2014.01.005

Related Literature

Article Analysis
・Effects of peginterferon alfa-2b (peg-intron)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.